COMPANY

A2 Biotherapeutics

HQ: Agoura Hills, CA source · a2bio.com ↗ · West Coast

Keywords: cell therapy oncology solid tumor solid tumors Colorectal Cancer Non Small Cell Lung Cancer Pancreatic Cancer CRC NSCLC Pancreas Cancer Mesothelioma Ovarian Cancer Colorectal Adenocarcinoma Ovarian Neoplasms Ovarian Carcinoma Malignant Mesothelioma Triple Negative Breast Cancer Recurrent NSCLC Non-Small Cell Squamous Lung Cancer Pancreatic Neoplasm Colon Cancer Rectal Cancer Lung Cancer Head and Neck Squamous Cell Carcinoma HNSCC Ovary Cancer Solid Tumor Cancer Solid Tumor, Unspecified, Adult Colorectal Carcinoma Small Cell Lung Cancer Head and Neck (HNSCC) Head and Neck Cancer Non-Small Cell Lung NSCLC (Non-small Cell Lung Cancer) Head and Neck Squamous Cell Cancer HNSCC Renal Cell Carcinoma RCC Kidney Cancer

Location: Agoura Hills, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Raises and deals from press releases

Raise Series C · $80M · announced Jan 9, 2025 Company release ↗
Source quote
- Jan 9, 2025 · Company release ↗
  “(A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column”

Raises announced in these releases: $80M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 31, 2025 Trial start —: A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products source ↗
May 22, 2025 Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression source ↗
Jan 9, 2025 Raise Series C · $80M source ↗
Apr 3, 2024 Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression source ↗
Apr 28, 2023 Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression source ↗
Oct 29, 2021 Trial start —: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression · NCT05736731
2028-06 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression · NCT06051695
2028-12 (ESTIMATED) · · Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · NCT04981119
Mar 31, 2029 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression · NCT06682793
Mar 31, 2030 (ESTIMATED) · · A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products · NCT06885424

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT04981119	Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing	Not listed	Recruiting	Oct 29, 2021	2028-12 (estimated)
NCT06051695	A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression	Phase 1/Phase 2	Recruiting	Apr 3, 2024	2028-06 (estimated)
NCT06885424	A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products	Not listed	Enrolling by invitation	Jul 31, 2025	Mar 31, 2030 (estimated)
NCT06682793	A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression	Phase 1/Phase 2	Recruiting	May 22, 2025	Mar 31, 2029 (estimated)
NCT05736731	A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression	Phase 1/Phase 2	Active, not recruiting	Apr 28, 2023	2026-12 (estimated)